mRNA technologies offer potential solutions for HIV-1 vaccine development by enabling rapid, safe and modular antigen design that can initiate rare antibody lineages required for broad protection. In this Review, we discuss preclinical and early clinical evidence, outline remaining challenges — particularly breadth and durability — and discuss delivery and manufacturing advances that may help translate these approaches into effective preventive and therapeutic strategies.
- Chuang Liu
- Alexey V. Yaremenko
- Wei Tao